A citation-based method for searching scientific literature

Emanuela Tumini, Emilia Herrera-Moyano, Marta San Martín-Alonso, Sonia Barroso, Carlos M Galmarini, Andrés Aguilera. Mol Cancer Res 2019
Times Cited: 16







List of co-cited articles
109 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line.
Anna F Farago, Benjamin J Drapkin, Jose Antonio Lopez-Vilarino de Ramos, Carlos M Galmarini, Rafael Núñez, Carmen Kahatt, Luis Paz-Ares. Future Oncol 2019
34
37

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
José Trigo, Vivek Subbiah, Benjamin Besse, Victor Moreno, Rafael López, María Angeles Sala, Solange Peters, Santiago Ponce, Cristian Fernández, Vicente Alfaro,[...]. Lancet Oncol 2020
71
31

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Leora Horn, Aaron S Mansfield, Aleksandra Szczęsna, Libor Havel, Maciej Krzakowski, Maximilian J Hochmair, Florian Huemer, György Losonczy, Melissa L Johnson, Makoto Nishio,[...]. N Engl J Med 2018
31

Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells.
Gema Santamaría Nuñez, Carlos Mario Genes Robles, Christophe Giraudon, Juan Fernando Martínez-Leal, Emmanuel Compe, Frédéric Coin, Pablo Aviles, Carlos María Galmarini, Jean-Marc Egly. Mol Cancer Ther 2016
50
25

Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.
E Calvo, V Moreno, M Flynn, E Holgado, M E Olmedo, M P Lopez Criado, C Kahatt, J A Lopez-Vilariño, M Siguero, C Fernandez-Teruel,[...]. Ann Oncol 2017
44
25

Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin.
Alejandro Losada, María José Muñoz-Alonso, Carolina García, Pedro A Sánchez-Murcia, Juan Fernando Martínez-Leal, Juan Manuel Domínguez, M Pilar Lillo, Federico Gago, Carlos M Galmarini. Sci Rep 2016
46
25

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Luis Paz-Ares, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J Hochmair, Mustafa Özgüroğlu, Jun Ho Ji,[...]. Lancet 2019
460
25

Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?
Luca Pompili, Carlo Leonetti, Annamaria Biroccio, Erica Salvati. J Exp Clin Cancer Res 2017
19
18

A review of trabectedin (ET-743): a unique mechanism of action.
Maurizio D'Incalci, Carlos M Galmarini. Mol Cancer Ther 2010
275
18

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.
Cristina Belgiovine, Ezia Bello, Manuela Liguori, Ilaria Craparotta, Laura Mannarino, Lara Paracchini, Luca Beltrame, Sergio Marchini, Carlos M Galmarini, Alberto Mantovani,[...]. Br J Cancer 2017
54
18

Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Bradley J Monk, Domenica Lorusso, Antoine Italiano, Stan B Kaye, Miguel Aracil, Adnan Tanović, Maurizio D'Incalci. Cancer Treat Rev 2016
28
18

Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production.
Paola Allavena, Mauro Signorelli, Marcello Chieppa, Eugenio Erba, Giancarlo Bianchi, Federica Marchesi, Chiara Omero Olimpio, Claudia Bonardi, Annalisa Garbi, Andrea Lissoni,[...]. Cancer Res 2005
210
18

Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity.
Wei Xie, Sabrina Forveille, Kristina Iribarren, Allan Sauvat, Laura Senovilla, Yan Wang, Juliette Humeau, Maria Perez-Lanzon, Heng Zhou, Juan F Martínez-Leal,[...]. Oncoimmunology 2019
16
18

NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018.
Gregory P Kalemkerian, Billy W Loo, Wallace Akerley, Albert Attia, Michael Bassetti, Yanis Boumber, Roy Decker, M Chris Dobelbower, Afshin Dowlati, Robert J Downey,[...]. J Natl Compr Canc Netw 2018
98
18

Comprehensive genomic profiles of small cell lung cancer.
Julie George, Jing Shan Lim, Se Jin Jang, Yupeng Cun, Luka Ozretić, Gu Kong, Frauke Leenders, Xin Lu, Lynnette Fernández-Cuesta, Graziella Bosco,[...]. Nature 2015
905
18

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
Charles M Rudin, M Catherine Pietanza, Todd M Bauer, Neal Ready, Daniel Morgensztern, Bonnie S Glisson, Lauren A Byers, Melissa L Johnson, Howard A Burris, Francisco Robert,[...]. Lancet Oncol 2017
267
18

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
Daniel Morgensztern, Benjamin Besse, Laurent Greillier, Rafael Santana-Davila, Neal Ready, Christine L Hann, Bonnie S Glisson, Anna F Farago, Afshin Dowlati, Charles M Rudin,[...]. Clin Cancer Res 2019
105
18

Telomeres in ICF syndrome cells are vulnerable to DNA damage due to elevated DNA:RNA hybrids.
Shira Sagie, Shir Toubiana, Stella R Hartono, Hagar Katzir, Aya Tzur-Gilat, Shany Havazelet, Claire Francastel, Guillaume Velasco, Frédéric Chédin, Sara Selig. Nat Commun 2017
54
12

Telomere length regulates TERRA levels through increased trimethylation of telomeric H3K9 and HP1α.
Nausica Arnoult, Amandine Van Beneden, Anabelle Decottignies. Nat Struct Mol Biol 2012
154
12

Telomere Length Determines TERRA and R-Loop Regulation through the Cell Cycle.
Marco Graf, Diego Bonetti, Arianna Lockhart, Kamar Serhal, Vanessa Kellner, André Maicher, Pascale Jolivet, Maria Teresa Teixeira, Brian Luke. Cell 2017
122
12

RNaseH1 regulates TERRA-telomeric DNA hybrids and telomere maintenance in ALT tumour cells.
Rajika Arora, Yongwoo Lee, Harry Wischnewski, Catherine M Brun, Tobias Schwarz, Claus M Azzalin. Nat Commun 2014
206
12

Telomeric RNA-DNA hybrids affect telomere-length dynamics and senescence.
Bettina Balk, André Maicher, Martina Dees, Julia Klermund, Sarah Luke-Glaser, Katharina Bender, Brian Luke. Nat Struct Mol Biol 2013
182
12

TERRA RNA binding to TRF2 facilitates heterochromatin formation and ORC recruitment at telomeres.
Zhong Deng, Julie Norseen, Andreas Wiedmer, Harold Riethman, Paul M Lieberman. Mol Cell 2009
355
12

Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin.
Gregory J Aune, Kazutaka Takagi, Olivier Sordet, Josée Guirouilh-Barbat, Smitha Antony, Vilhelm A Bohr, Yves Pommier. Clin Cancer Res 2008
35
12

Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase.
Tatiana Okouneva, Olga Azarenko, Leslie Wilson, Bruce A Littlefield, Mary Ann Jordan. Mol Cancer Ther 2008
147
12

Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells.
Carlos M Galmarini, Maud Martin, Benjamin Pierre Bouchet, María José Guillen-Navarro, Marta Martínez-Diez, Juan Fernando Martinez-Leal, Anna Akhmanova, Pablo Aviles. BMC Cancer 2018
16
12

Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.
Simon J Harrison, Paul Mainwaring, Timothy Price, Michael J Millward, Peeter Padrik, Craig R Underhill, Paul K Cannell, Steven D Reich, Mohit Trikha, Andrew Spencer. Clin Cancer Res 2016
39
12

Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA.
M Bonfanti, E La Valle, J M Fernandez Sousa Faro, G Faircloth, G Caretti, R Mantovani, M D'Incalci. Anticancer Drug Des 1999
82
12

First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors.
Elena Elez, Carlos Gomez-Roca, Arturo Soto Matos-Pita, Guillem Argiles, Thibaud Valentin, Cinthya Coronado, Jorge Iglesias, Teresa Macarulla, Sarah Betrian, Salvador Fudio,[...]. Invest New Drugs 2019
8
25

CD30-targeted antibody therapy.
Anas Younes. Curr Opin Oncol 2011
39
12

A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.
Bradley J Monk, John A Blessing, Daron G Street, Carolyn Y Muller, James J Burke, Martee L Hensley. Gynecol Oncol 2012
66
12

Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation.
S Jin, B Gorfajn, G Faircloth, K W Scotto. Proc Natl Acad Sci U S A 2000
183
12

Counting on natural products for drug design.
Tiago Rodrigues, Daniel Reker, Petra Schneider, Gisbert Schneider. Nat Chem 2016
408
12

Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
B C Potts, M X Albitar, K C Anderson, S Baritaki, C Berkers, B Bonavida, J Chandra, D Chauhan, J C Cusack, W Fenical,[...]. Curr Cancer Drug Targets 2011
147
12

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.
R Garcia-Carbonero, J G Supko, R G Maki, J Manola, D P Ryan, D Harmon, T A Puchalski, G Goss, M V Seiden, A Waxman,[...]. J Clin Oncol 2005
154
12



Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.
Giovanni Grignani, Lorenzo D'Ambrosio, Ymera Pignochino, Emanuela Palmerini, Massimo Zucchetti, Paola Boccone, Sandra Aliberti, Silvia Stacchiotti, Rossella Bertulli, Raimondo Piana,[...]. Lancet Oncol 2018
31
12

Brentuximab vedotin.
Anas Younes, Uma Yasothan, Peter Kirkpatrick. Nat Rev Drug Discov 2012
84
12

XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic alkaloids.
Sascha Feuerhahn, Christophe Giraudon, Marta Martínez-Díez, Juan A Bueren-Calabuig, Carlos M Galmarini, Federico Gago, Jean-Marc Egly. Chem Biol 2011
30
12

Enriching cancer pharmacology with drugs of marine origin.
Paula C Jimenez, Diego V Wilke, Paola C Branco, Anelize Bauermeister, Paula Rezende-Teixeira, Susana P Gaudêncio, Leticia V Costa-Lotufo. Br J Pharmacol 2020
30
12



Marine organisms as a source of new anticancer agents.
G Schwartsmann, A Brondani da Rocha, R G Berlinck, J Jimeno. Lancet Oncol 2001
93
12

Marine natural products.
John W Blunt, Anthony R Carroll, Brent R Copp, Rohan A Davis, Robert A Keyzers, Michèle R Prinsep. Nat Prod Rep 2018
327
12

Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas.
Monica M Mita, Matthew A Spear, Lorrin K Yee, Alain C Mita, Elisabeth I Heath, Kyriakos P Papadopoulos, Kristine C Federico, Steven D Reich, Ofelia Romero, Lisa Malburg,[...]. Clin Cancer Res 2010
66
12

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.
Claudia Forni, Mario Minuzzo, Emanuela Virdis, Elena Tamborini, Matteo Simone, Michele Tavecchio, Eugenio Erba, Federica Grosso, Alessandro Gronchi, Pierre Aman,[...]. Mol Cancer Ther 2009
140
12

Marine Natural Products in Medicinal Chemistry.
Carlos Jiménez. ACS Med Chem Lett 2018
59
12

Efficacy of eribulin in breast cancer: a short report on the emerging new data.
Gelareh Eslamian, Caroline Wilson, Robin J Young. Onco Targets Ther 2017
4
50

The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.
Alan F Wahl, Kerry Klussman, Jennifer D Thompson, Judy H Chen, Leigh V Francisco, Grant Risdon, Dana F Chace, Clay B Siegall, Joseph A Francisco. Cancer Res 2002
155
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.